Abstract
A prospective randomized study on aggressive non-Hodgkin's lymphomas was conducted by investigators at several Italian institutions with the intent of comparing two third-generation conceptually different regimens: the regimen containing methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B), a short-term continuous twelve-week therapy, and F-MACHOP (5-fluorouracil, methotrexate with leucovorin rescue, cytarabine, cyclophosphamide, doxorubicin, vincristine, and prednisone), a monthly intensive cyclic treatment combining prednisone with six active non-cross-resistant cytotoxic drugs. The goals of this study were the response rate, relapse-free survival, and incidence of hematologic and nonhematologic toxicities. Two hundred-eighty-six patients included between 15 and 60 years fulfilled the criteria for entry to the study; 140 patients were treated with MACOP-B and 146 with F-MACHOP. The minimum follow-up was 24 months. Clinical characteristics of all patients were similar and known prognostic factors were equally distributed between the two groups. Complete remission (CR) was achieved by 61% and 67% of the patients treated with MACOP-B and F-MACHOP, respectively; 4% a...Continue Reading
References
Jan 1, 1990·Blut·W OsterW Thoenes
Jan 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoR I Fisher
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B CoiffierJ O Armitage
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J HoskinsJ M Connors
May 1, 1991·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C GuglielmiF Mandelli
Jul 1, 1985·Annals of Internal Medicine·M Coleman
Oct 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R LeeE J Freireich
May 1, 1985·Annals of Internal Medicine·P Klimo, J M Connors
Feb 6, 1988·Lancet·A G StansfeldO Mioduszewska
Jan 1, 1986·Clinical and Laboratory Haematology·P J Darbyshire, M G Mott
Oct 1, 1986·Scandinavian Journal of Haematology·S TuraM Baccarani
Jan 1, 1987·Cancer Investigation·C GuglielmiF Mandelli
Feb 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A T SkarinE Frei
Nov 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Hryniuk, H Bush
Mar 1, 1983·Annals of Internal Medicine·R I FisherR C Young
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Mar 1, 1994·British Journal of Haematology·S PileriP Mazza
Apr 8, 1993·The New England Journal of Medicine·R I FisherT P Miller
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Citations
Jan 1, 1994·Medical Oncology·P J Bierman
Dec 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P L ZinzaniS Tura
Oct 23, 1998·Leukemia Research·J DreiherP Raamami
Jan 27, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L LeeM Crump
Jun 12, 1999·The American Journal of Surgical Pathology·G Fraternali-OrcioniS A Pileri
Mar 1, 1994·British Journal of Haematology·S PileriP Mazza
Apr 1, 1996·Leukemia & Lymphoma·P L ZinzaniS Tura
Jun 1, 1996·Leukemia & Lymphoma·P L ZinzaniS Tura
Feb 5, 2011·Chemistry : a European Journal·Hisatsugu YamadaSei-Ichi Nishimoto
Feb 2, 2011·Journal of Nanobiotechnology·Nianxi ZhaoYouli Zu
Jun 18, 2004·The Journal of Biological Chemistry·Riccardo ChiariniRoberto P Revoltella
Nov 1, 1996·European Journal of Haematology·E MontserratJ Estapé
Apr 1, 1995·British Journal of Haematology·B FaliniL Pasqualucci